Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/03/2005US20050244501 Water-soluble stabilized self-assembled polyelectrolytes
11/03/2005US20050244500 Intravitreal implants in conjuction with photodynamic therapy to improve vision
11/03/2005US20050244498 cores comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol, gelling agents and excipients, having sustained release coatings; higher bioavailability and side effect reduction
11/03/2005US20050244496 Controlled-release sedative-hypnotic compositions and methods related thereto
11/03/2005US20050244495 Tranexamic acid formulations
11/03/2005US20050244494 Controlled releases system containing temozolomide
11/03/2005US20050244491 Fast disintegrating meloxicam tablet
11/03/2005US20050244490 Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
11/03/2005US20050244489 Liquid compositions for soft sustained-release capsules and method for production
11/03/2005US20050244486 Topical methadone compositions and methods for using the same
11/03/2005US20050244485 Transdermal administration of hydrophilic drugs using a basic permeation enhancer composition
11/03/2005US20050244479 Sustained release intraocular implants and methods for preventing retinal dysfunction
11/03/2005US20050244478 Anti-excititoxic sustained release intraocular implants and related methods
11/03/2005US20050244477 Tyrosine kinase microsphers
11/03/2005US20050244476 Intraocular implants and methods for improving vision
11/03/2005US20050244475 Biodegradable intravitreal tyrosine kinase implants
11/03/2005US20050244474 Steroid-containing sustained release intraocular implants and related methods
11/03/2005US20050244473 Memantine intravitreal implants
11/03/2005US20050244472 Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
11/03/2005US20050244471 Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
11/03/2005US20050244470 Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer; pharmacokinetics
11/03/2005US20050244469 Inserting an implant into an ocular site; an active agent and a polymer carrier; releasing the active agent from the implant
11/03/2005US20050244468 Sustained release intraocular implants and related methods
11/03/2005US20050244467 Extended release biodegradable ocular implants
11/03/2005US20050244466 Photodynamic therapy in conjunction with intraocular implants
11/03/2005US20050244465 Drug delivery systems and methods for treatment of an eye
11/03/2005US20050244464 Hypotensive lipid-containing biodegradable intraocular implants and related methods
11/03/2005US20050244463 Sustained release intraocular implants and methods for treating ocular vasculopathies
11/03/2005US20050244461 Controlled release drug delivery systems and methods for treatment of an eye
11/03/2005US20050244454 Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins
11/03/2005US20050244433 Administering vaccine comprising human papillomavirus L1 protein and excludes E protein to induce immune response
11/03/2005US20050244425 Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
11/03/2005US20050244424 Carbohydrate-based synthetic vaccines for hiv
11/03/2005US20050244414 Method to ameliorate osteolysis and metastasis
11/03/2005US20050244413 Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
11/03/2005US20050244407 Therapeutic synergy of anti-cancer compounds
11/03/2005US20050244393 Sealant or tissue generating product
11/03/2005US20050244386 Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
11/03/2005US20050244381 Adenovirus including a gene coding for a superoxide dismutase
11/03/2005US20050244380 Immunomodulatory oligonucleotides
11/03/2005US20050244379 Using oligonucleotide complexes comprising phosphorothioate backbone to enhance antigen-specific immune response; antisense therapies; gene expression inhibition; viricides
11/03/2005US20050244368 Pre-endoscopic use of polyethylene glycol compositions
11/03/2005US20050244367 Phospholipase inhibitors localized in the gastrointestinal lumen
11/03/2005US20050244366 Dressing and method of treatment for a wound
11/03/2005US20050244365 Methods, compositions, formulations, and uses of cellulose and acrylic-based polymers
11/03/2005US20050244364 Novel polymers, compositions comprising them, processes therefor, and use thereof
11/03/2005US20050244363 Hyaluronic acid based copolymers
11/03/2005US20050244359 Topical regulation of triglyceride metabolism
11/03/2005US20050244358 Use of mixture of sodium hyaluronate and chondroitin sulfate for use in products and therapies for cosmetic surgery
11/03/2005US20050244341 Aerodynamically light particles for pulmonary drug delivery
11/03/2005US20050244340 Dry powder compositions
11/03/2005US20050244332 Contrast agents for myocardial perfusion imaging
11/03/2005DE19910403B4 3-Hydroxy-1,2,3,3a-tetrahydro-benzo[b]cyclopent[e]azepin-4,10(5H,10aH)-dion-Derivate enthaltende Arzneimittel 3-hydroxy-1,2,3,3a-tetrahydro-benzo [b] cyclopent [e] azepine-4,10 (5H, 10AH) -dione derivatives of drugs containing
11/03/2005DE102005010142A1 Composition for activating hair roots, especially to combat androgenetic alopecia, containing synergistic combination of caffeine and plant extract with phyto-estrogenic action
11/03/2005DE102004018796A1 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel Selected CGRP antagonists, processes for their preparation and their use as medicaments
11/03/2005DE102004017996A1 Stable anionic liposome depot system for prolonged release of protein or peptide drugs, e.g. insulin, comprising phosphatidyl choline, cholesterol, anionic lipid(s) and cationic polymer
11/03/2005DE102004017438A1 Hetaryloxy-substituierte Phenylaminopyrimidine Hetaryloxy-substituted Phenylaminopyrimidine
11/03/2005DE102004016355A1 Herstellung und Verwendung des Konjugats Methotrexat-Albumin als Mittel zur Immunosuppression bei GVHD Manufacture and use of the conjugate of methotrexate albumin as a means of immunosuppression in GVHD
11/03/2005DE102004015752A1 Treating or preventing renal diseases, especially renal ischemia, post ischemia and (re)perfusion disorders, using gabapentin lactam as cytoprotective preconditioning agent
11/03/2005DE102004009154A1 Novel combination of hexyl 2-(4-diethylamino-2-hydroxybenzoyl)-benzo ate and triheptylin is used as a light stabilizer especially in cosmetics or dermatological compositions
11/03/2005DE102004008017A1 Increasing nutrient bioavailability comprises administering a dietary supplement together with a galactomannan or glucomannan
11/03/2005CA2835840A1 Beneficial effects of increasing local blood flow
11/03/2005CA2807787A1 Hmb compositions and uses thereof
11/03/2005CA2802600A1 Use of flibanserin in the treatment of female sexual disorders
11/03/2005CA2581488A1 Alkaloid compounds and their use as anti-malarial drugs
11/03/2005CA2567249A1 Lithium combinations, and uses related thereto
11/03/2005CA2565219A1 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments
11/03/2005CA2564727A1 Angiostatic agents for controlling choroidal neovascularisation after ocular surgery of trauma
11/03/2005CA2564574A1 Use of c-kit inhibitors for treating fibrosis
11/03/2005CA2564570A1 Use of c-kit inhibitors for treating plasmodium related diseases
11/03/2005CA2564568A1 Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
11/03/2005CA2564436A1 Use of chondroitin sulphate e (cs-e ) for the treatment of disease or conditions related to collagen fibril formation.
11/03/2005CA2564356A1 Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
11/03/2005CA2564353A1 Galantamine salts, method of producing it and nasal composition thereof
11/03/2005CA2564161A1 Melatonin and its use in preventing postoperative complications
11/03/2005CA2564137A1 Treatment of fungal infections
11/03/2005CA2564066A1 Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
11/03/2005CA2564019A1 Lozenge for delivery of dextromethorphan
11/03/2005CA2563952A1 Use of the pregnane glycosides in the treatment/management of obesity, obesity-related and other disorders
11/03/2005CA2563826A1 Treatment of cns disorders using cns target modulators
11/03/2005CA2563759A1 6,7-dihydroxy-8-phenyl-3,6,7,8-tetrahydro-chromeno[7, 8-d]imidazole derivatives and their use as gastric acid secretion inhibitors
11/03/2005CA2563756A1 Phenyl acetamides
11/03/2005CA2563752A1 Compositions of allosteric hemoglobin modifiers and methods of making the same
11/03/2005CA2563751A1 Crystalline and amorphous forms of efaproxiral sodium
11/03/2005CA2563749A1 Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
11/03/2005CA2563748A1 Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
11/03/2005CA2563744A1 Composition comprising a diuretic and/or cardiac glycoside for the treatment of dna viral infections of the eye
11/03/2005CA2563743A1 New pharmaceutical compositions for the treatment of sexual disorders ii
11/03/2005CA2563741A1 Antisense oligonucleotides against cpla2, compositions and uses thereof
11/03/2005CA2563707A1 Method of treating neuropathic pain using a crth2 receptor antagonsit
11/03/2005CA2563687A1 Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
11/03/2005CA2563684A1 Preventive and/or therapeutic agent for chronic sinusitis
11/03/2005CA2563680A1 Seamless capsule containing water-soluble active substance
11/03/2005CA2563678A1 Beneficial effects of increasing local blood flow
11/03/2005CA2563670A1 Transdermal delivery of beneficial substances effected by a hostile biophysical environment
11/03/2005CA2563665A1 Method of stabilizing disordered cefovecin sodium salt
11/03/2005CA2563635A1 Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
11/03/2005CA2563617A1 Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives
11/03/2005CA2563556A1 Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
11/03/2005CA2563494A1 Urea derivatives as antagonists of the vanilloid receptor (vr1)
1 ... 4482 4483 4484 4485 4486 4487 4488 4489 4490 4491 4492 4493 4494 4495 4496 4497 4498 4499 4500 4501 4502 ... 7860